| Issue Date | Title | Author(s) |
| 2009-08-01 | Living with hepatitis C and treatment: The personal experiences of patients | Sgorbini, M; O'Brien, L; Jackson, D |
| 2018-01-01 | Factors associated with non-adherence to HBV antiviral therapy | Sheppard-Law, S; Zablotska-Manos, I; Kermeen, M; Holdaway, S; Lee, A; George, J; Zekry, A; Maher, L |
| 2011-04-18 | Predictors of deferral of treatment for hepatitis C infection in Australian clinics | Gidding, HF; Law, MG; Amin, J; MacDonald, GA; Sasadeusz, JJ; Jones, TL; Strasser, SI; George, J; Dore, GJ |
| 2017-01-01 | Factors associated with HBV virological breakthrough | Sheppard-Law, S; Zablotska-Manos, I; Kermeen, M; Holdaway, S; Lee, A; Zekry, A; Dore, GJ; George, J; Maher, L |
| 2020-01 | COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. | Aljabali, AAA; Bakshi, HA; Satija, S; Meenu,; Prasher, P; Ennab, RM; Chellappan, DK; Gupta, G; Negi, P; Goyal, R; Sharma, A; Mishra, V; Dureja, H; Dua, K; Tambuwala, MM |
| 2023-03-01 | Barriers and Facilitators to Hepatitis C Virus (HCV) Treatment for Aboriginal and Torres Strait Islander Peoples in Rural South Australia: A Service Providers' Perspective. | Lim, D; Phillips, E; Bradley, C; Ward, J |
| 2011-12-01 | Brain distribution of ribavirin after intranasal administration | Colombo, G; Lorenzini, L; Zironi, E; Galligioni, V; Sonvico, F; Balducci, AG; Pagliuca, G; Giuliani, A; Calzà, L; Scagliarini, A |
| 2009-08-12 | Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections | Sonvico, F; Colombo, G; Gallina, L; Bortolotti, F; Rossi, A; McInnes, CJ; Massimo, G; Colombo, P; Scagliarini, A |
| 2016-04-01 | Strengthening public health systems: Assessing the attributes of the NSW influenza surveillance system | Dawson, G; Gilmour, R; Tobin, S; Travaglia, J |
| 2019-08-15 | Recent update on anti-dengue drug discovery | Dighe, SN; Ekwudu, O; Dua, K; Chellappan, DK; Katavic, PL; Collet, TA |
